Bolivia’s Bet on Rotavirus Vaccines Pays Off
Ciro de Quadros is mentioned in PATH's Rotavirus Vaccine Update.
Vaccine impact studies, like this one in Bolivia, are crucial for providing high-quality evidence to countries considering the use of rotavirus vaccines by demonstrating the real-world effectiveness in similar high-mortality settings. A large clinical trial assessed the efficacy of RV1 in ten Latin American countries, most of which were upper-middle income countries. Bolivia, a high mortality, lower-middle income country, was not one of those ten countries where the clinical trial was conducted. The study released today found that vaccine performance in Bolivia was quite high and nearly as similar to the efficacy seen in the clinical trial conducted in those other ten countries (~85 percent) and clearly demonstrates that rotavirus vaccines are proven and effective in high-mortality, low and lower-middle income settings. In countries where disease burden is high, rotavirus vaccines will have a greater impact even at a lower efficacy rate, because they will substantially reduce severe disease responsible for hospitalization and death.